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ABSTRACT: A 12-step asymmetric synthesis of thromboxane B2 (TxB2) from 2,5-dimethoxytetrahydrofuran is described. The syn-
thesis employs our organocatalytic aldol reaction of succinaldehyde to give a key bicyclic enal intermediate. From here, the synthetic 
strategy involves a conjugate addition of an alkenyl side chain to the bicyclic enal, Baeyer-Villiger oxidation, and a highly Z-selective 
Wittig olefination of hemiacetals. Key to success was selecting the timing of the appropriate oxidation state of the different functional 
groups. 
Thromboxane B2 (TxB2) is a metabolite of thromboxane A2 (TxA2, 
t l/2 (37 °C) = 32 s at pH 7.40), a prostanoid which causes contrac-
tion of coronary vessels and platelet aggregation (throm-
bosis)(Scheme 1).1 Although TxB2 is generally regarded as biolog-
ically inert, there are reports that it inhibits the pulmonary inactiva-
tion of PGE2,2 and that it may play a role in the immune3  and vas-
cular systems too.4 It’s main use is as a marker for TxA2 and it is 
recognized as a valuable molecule for the studies of prostanoid-re-
lated biochemical processes.5 For example, Still employed TxB2 as 
a synthetic precursor to the biologically active TxA2.5a,6  The inter-
esting molecular architecture of the natural product TxB2 has made 
it an appealing target for chemists over the years.7 In this context, 
several asymmetric syntheses of TxB2 have been reported.8 How-
ever, the previous synthetic strategies are rather lengthy and lack 
atom economy, costing time and energy, and so improved synthe-
ses are still in demand.  
 
 
Figure 1. Structures of thromboxane A2 and thromboxane B2. 
 
We recently developed a short synthetic strategy to prostaglandins, 
completing the total synthesis of PGF2α in just 7 steps9a and applied 
this methodology to several prostaglandin-based drugs9b,9c and to 
12-PGJ3.9d The key step in the synthesis employed a (L)-proline 
catalysed double aldol dimerization of succinaldehyde to prepare 
the key bicyclic enal intermediate (8).9a,d We were keen to broaden 
the reach of this chemistry and in particular to demonstrate its 
application to other prostanoids. Just as the Corey lactone10 has 
been used for the preparation of a wide range of prostanoids, we 
see our enal intermediate, 8, as being perfectly set up for further 
transformations to access the whole family of prostanoids in an ef-
ficient manner. As part of this effort, we now report the application 
of this strategy to a 12-step synthesis of the natural prostanoid 
TxB2.11   
 
Scheme 1. Retrosynthetic analysis of thromboxane B2 from the key 




Our retrosynthetic analysis for the stereoselective synthesis of 
TxB2 is shown in Scheme 1. We envisaged that the α-side chain 
 
 
could be introduced by a Wittig reaction on the corresponding hem-
iacetal 3. This could be obtained by selective reduction of lactone 
4, which itself could be synthesized by Baeyer-Villiger oxidation 
of ketone 5. Ketone 5 could be generated from a stereoselective 
conjugate addition of the chiral -side chain 6 to the key enal in-
termediate 7 followed by ozonolysis. Although selective redox 
steps are required (4→3), this analysis was deemed preferable over 
using the acetal since (i) the lactone is a crystalline compound (ii) 
it is a single diastereoisomer whereas the acetal is a mixture and 
(iii) it minimizes the use of protecting groups.  
We began our synthesis with the preparation of enal-lactone 7, 
available in just 3 steps on multigram scale with high ee using our 
L-proline-catalyzed double aldol reaction of succinaldehyde (9), 
generated by hydrolysis of commercially obtainable 2,5-dimethox-
ytetrahydrofuran (Scheme 2).9 Subsequent conjugate addition of 
the mixed vinyl cuprate 10 to 7 followed by trapping with TMSCl 
and selective ozonolysis9a,9b gave ketone 11 which was then con-
verted to the dilactone intermediate 12 via Baeyer-Villiger oxida-
tion12 [20% yield (unoptimized), over 3 steps]. Unfortunately, all 
attempts to selectively reduce dilactone 12 to the corresponding 
Wittig reaction precursor 14 via the formation of 13 using Proctor’s 
SmI2-H2O method13 led to complex reaction mixtures (see SI for 
detailed information). Although this method had been reported to 
reduce 6 membered lactones to the diol in the presence of 5 mem-
bered ring lactones, we observed the formation of multiple reaction 
products when applied to dilactone 12.  
 




Reagents and conditions: (a) [Cu(MeCN)4]OTf (5 mol %), 2'-Bi-
pyridine (5 mol %), TEMPO (5 mol %), NMI (10 mol %), CH3CN, 
Air, r.t., overnight, 91% yield. (b) Cuprate 10 (1.2 eq.), THF/Et2O, 
−78 °C; then TMSCl (5 eq.), Et3N (6 eq.), −78 °C to −20 °C. (c) 
O3-O2, CH2Cl2/MeOH (v/v, 3:1), −78 °C; then PPh3 (1.5 eq.). (d) 
m-CPBA (2.5 eq.), NaHCO3 (2.7 eq.), CH2Cl2, 0 °C to r.t., 36 h, 
20% yield, 3 steps. TEMPO, 2,2,6,6-tetramethyl-1-piperidinyloxy. 
NMI, N-methylimidazole. TBS, tert-butyldimethylsilyl. TMS, tri-
methylsilyl. m-CPBA, m-chloroperoxybenzoic acid. DDQ, 2,3-di-
chloro-5,6-dicyano-1,4-benzoquinone. 
 
Due to the difficulty in selectively reducing one of the two lactones, 
we decided to begin with the acetal in place, since the hemiacetal 
is formed directly from the proline catalyzed aldol reaction.  Fur-
thermore, this would avoid additional oxidation and reduction 
steps. We selected the para-methoxybenzyl acetal 15 to aid depro-
tection under neutral conditions (Scheme 3). Although this route 
has the acetal at the required oxidation state, it is complicated by 
the having to manipulate and carry through two diastereoisomers. 
In fact, we found it better to separate the acetal diastereomers and 
manipulate them separately, as this allowed us to monitor reactions 
more easily and purify and characterize compounds more fully. In-
itially, the major -isomer of the acetals was selected, and we car-
ried through the established 1,4-addition/ozonolysis/Baeyer-Vil-
liger oxidation, delivering the key lactone intermediate -17 (64% 
yield, over 3 steps). Following PMB deprotection with DDQ, we 
explored the Wittig reaction with (4-carboxybutyl)triphenyl-phos-
phonium bromide or [4-(4-Methyl-2,6,7-trioxabicyclo[2.2.2]oct-1-
yl)butyl]triphenylphosphonium iodide14 but these invariably led to 
intractable mixtures (Scheme 3b). We suspected that under basic 
conditions, the lactone moiety in intermediate 18 was interfering in 
this step causing side reactions, and so we decided to remove it. 
Initially, we considered reduction to the diol since, as shown in 
Scheme 3b, this could lead to a short synthesis of TxB2, simply 
requiring reduction, Wittig reaction, selective oxidation and depro-
tection. Unfortunately, whilst LiAlH4 reduction to diol 20 was suc-
cessful we were unable to deprotect the PMB group cleanly.  
We therefore considered an alternative strategy in which we con-
ducted a controlled reduction of the lactone to the required oxida-
tion state and employed a protecting group instead, i.e. conversion 
of lactone -17 into the methoxy acetal. Starting with -17, reduc-
tion (DIBAL-H, THF, –78 °C) and oxy-methylation of the “naked” 
anion generated by deprotonation with KHMDS in the presence of 
18-crown-6, afforded acetal -22 as a single diastereoisomer.15 The 
established 1,4-addition/ozonolysis/Baeyer-Villiger oxidation pro-
tocol was also applied to the minor α-isomer of PMB-acetals 15, 
affording lactone α-17 in 63% yield over 3 steps. Reduction with 
DIBAL-H, followed by oxy-methylation again furnished a single 
diastereomer α-22. Interestingly, the α- and β-isomers of hemiace-
tal 21 showed quite different reactivity: the α-isomer was far more 
labile under oxy-methylation conditions than the β-isomer giving 
several un-identified side products (36% yield for α vs. 73% yield 
for β). Following PMB deprotection of acetals 22 with DDQ, Wit-
tig olefination using phosphonium salt 24 with t-BuOK now suc-
cessfully gave the corresponding alkene 25 in 97% yield with Z/E 
> 95:5. Desilylation of the TBS group with TBAF gave the required 
thromboxane B2 methyl glycoside 26 in 89% yield. Finally, sub-
jecting methyl glycoside 26 to hydrolysis with excess Dowex-50 




Scheme 3. Completion of the synthesis of thromboxane B2  
 
Reagents and conditions: (a) PMBOH (2 eq.), Amberlyst 15 (cat.), MgSO4 (2.5 eq.), CH2Cl2, 0 °C to r.t., 24 h; then MnO2 (6 eq.), r.t., 12 h, 
81% yield, 1.7:1 β/α. (b) Cuprate 10 (1.2 eq.), THF/Et2O, −78 °C; then TMSCl (5 eq.), Et3N (6 eq.), −78 °C to −20 °C. (c) O3-O2, 
CH2Cl2/MeOH (v/v, 3:1), −78 °C; then PPh3 (1.5 eq.). (d) m-CPBA (2.5 eq.), NaHCO3 (2.7 eq.), CH2Cl2, 0 °C to r.t., 36 h, 64% yield for β, 
63% yield for α, 3 steps. (e) DIBAL-H (3.0 eq.), THF, −78 °C, 3 h, 96% yield for β, 91% yield for α. (f) MeI (3 eq.), KHMDS (1.1 eq.), 18-
Crown-6 (1.1 eq.), THF, −78 °C, 18 h, single diastereomer, 73% yield for β, 36% yield for α. (g) DDQ (1.5 eq.), CH2Cl2/H2O (v/v, 9:1), 0 
°C to r.t., 6 h, 80% yield for β, 74% yield for α. (h) (4-carboxybutyl)triphenyl-phosphonium bromide (4 eq.), t-BuOK (8 eq.), THF, 0 °C to 
r.t., 2 h, 97% yield with Z/E > 95:5. (i) TBAF (2 eq.), THF, 0 °C to r.t.,12 h, 89% yield. (j) Dowex-50 Resin, H2O, r.t., 16 h, 90% yield. (k) 
DDQ (1.5 eq.), CH2Cl2/H2O (v/v, 9:1), 0 °C to r.t., 6 h, 81% yield. (l) LiAlH4 (1.2 eq.), THF, 0 °C to r.t., 6 h, 90% yield. (m) DDQ (1.5 eq.), 
CH2Cl2/H2O (v/v, 9:1), 0 °C to r.t., 6 h, messy. p-methoxybenzyl. TBS, tert-butyldimethylsilyl. TMS, trimethylsilyl. m-CPBA, m-chloroper-
oxybenzoic acid. DIBAL-H, diisobutylaluminum hydride. HMDS, bis(trimethylsilyl)amide. DDQ, 2,3-dichloro-5,6-dicyano-1,4-benzoqui-
none. TBAF, tetrabutylammonium fluoride. 
 
In conclusion, we have developed a highly stereoselective synthe-
sis of thromboxane B2 in 12 steps with an overall yield of 5%, uti-
lizing our key enal intermediate, which is readily available in two 
steps by a L-proline-catalyzed aldol dimerization of succinaldehyde 
in high ee. The key features include an efficient 1,4-addition/ozo-
nolysis/Baeyer-Villiger oxidation protocol, and a Wittig olefina-
tion of hemiacetals with excellent levels of Z selectivity. Although 
carrying through the diastereomeric acetals complicates analysis, it 
avoids additional redox steps enabling the synthesis to be com-
pleted in short order. The synthesis adds to the growing list of 
 
 
prostanoids that can now be accessed from our key enal intermedi-
ate, available on scale in high enantioselectivity in just two steps. 
ASSOCIATED CONTENT  
Supporting Information 
The Supporting Information is available free of charge on the ACS 
Publications website. 
 
General procedures, characterization data, and copies of NMR 
spectra for all novel compounds. 
AUTHOR INFORMATION 
Corresponding Author 
* v.aggarwal@bristol.ac.uk (Varinder K. Aggarwal).  
ORCID 
Changcheng Jing: 0000-0002-2376-1828 
Varinder K. Aggarwal: 0000-0003-0344-6430 
 
Notes 
The authors declare no competing financial interests. 
ACKNOWLEDGMENT  
We thank EPSRC (EP/M012530/1) for financial support. We thank 
Riccardo Mega (University of Bristol) and Steven Bennett (Univer-
sity of Bristol) for useful discussions. 
REFERENCES 
(1) (a) Hamberg, M.; Svensson, J.; Samuelsson, B. Thromboxanes: A 
New Group of Biologically Active Compounds Derived from Prosta-
glandin Endoperoxides. Proc. Natl. Acad. Sci. U.S.A. 1975, 72, 2994-
2998. (b) Fried, J.; Zhou, Z.; Chen, C.-K. On the Structure of Throm-
boxane A2. Tetrahedron Lett. 1984, 25, 3271–3272. 
(2) (a) Boura, A. L. A.; Murphy, R. D. Thromboxane B2 Inhibits Pros-
taglandin E2 Inactivation by the Rat Isolated Perfused Lung. Clin. Exp. 
Pharmacol. Physiol. 1978, 5, 387–392. (b) Fitzpatrick, T. M.; Fried-
man, L. S.; Kot, P. A.; Ramwell, P. W. Tromboxane B2 Inhibits the 
Pulmonary Inactivation of Prostaglandin E2 in the Dog. Br. J. Pharma-
col. 1980, 70, 295–299.  
(3) Morchón, R.; Carretón, E; García, R.; Zueva, T.; Kartashev, V.; 
Simón, F. A. Possible Relationship Between Thromboxane B2 and Leu-
kotriene B4 and the Encapsulation of Dirofilaria Repens Worms in Hu-
man Subcutaneous Dirofilariasis. J. Helminthol. 2019, 94, 1–3. 
(4) Friedman, L. S.; Fitzpatrick, T. M.; Bloom, M. F.; Ramwell, P. W., 
Rose, J. C.; Kot, P. A. Cardiovascular and Pulmonary Effects of 
Thromboxane B2 in the Dog. Circ Res. 1979, 44, 748–751. 
(5) (a) Bhagwat, S. S.; Hamann, P. R.; Still, W. C. Synthesis of Throm-
boxane A2. J. Am. Chem. Soc. 1985, 107, 6372–6376. (b) Maddens, B. 
E.J.; Daminet, S.; Demeyere, K.; Demon, D.; Smets, P.; Meyer, E. Val-
idation of Immunoassays for the Candidate Renal Markers C-Reactive 
Protein, Immunoglobulin G, Thromboxane B2 and Retinol Binding 
Protein in Canine Urine. Vet. Immunol. Immunopathol. 2010, 134, 259–
264. (c) Minet, V.; Evrard, J.; Vancraeynest, C.; Dogné, J-M.; Mullier, 
F.; Pochet, L. Development and Validation of a Liquid Chromatog-
raphy/Tandem Mass Spectrometry Method for the Simultaneous Quan-
tification of Serotonin and Thromboxane B2 from Activated Platelets. 
Int. J. Lab. Hem. 2018, 40, 663–671. (d) Narumiya, S.; Sugimoto, Y.; 
Ushikubi, F. Prostanoid Receptors: Structures, Properties, and Func-
tions. Physiol. Rev. 1999, 79, 1193–1226. (e) Breyer, R. M.; Bagdas-
sarian, C. K.; Myers, S. A.; Breyer, M. D. Prostanoid Receptors: Sub-
types and Signaling. Annu. Rev. Pharmacol. Toxicol. 2001, 41, 661–
690. (f) Ricciotti, E.; FitzGerald, G. A. Prostaglandins and Inflamma-
tion. Arterioscler. Thromb. Vasc. Biol. 2011, 31, 986–1000. 
(6) Bhagwat, S. S.; Hamann, P. R.; Still, W. C.; Bunting, S.; Fitzpat-
rick, F. A. Synthesis and Structure of the Platelet Aggregation Factor 
Thromboxane A2. Nature 1985, 315, 511–513. 
(7) Reviews, see: (a) Nicolaou, K. C.; Gasic, G. P.; Barnette, W. E. 
Synthesis and Biological Properties of Prostaglandin Endoperoxides, 
Thromboxanes and Prostacyclins. Angew. Chem., Int. Ed. Engl. 1978, 
17, 293–312. (b) Newton, R. F.; Roberts, S. M. Synthesis 1984, 449–
478. (c) Pelyvás, I. F.; Thiem, J.; Tóth, Z. G. Access to Thromboxane 
Compounds: Syntheses from Carbohydrates, as Natural Chiral Pools. 
J. Carbohydr.Chem. 1998, 17, 1–26. 
(8) (a) Nelson, N. A.; Jackson, R. W. Total Synthesis of Thromboxane 
B2. Tetrahedron Lett. 1976, 17, 3275–3278. (b) Kelly, R. C.; Schletter, 
I.; Stein, S. J. Synthesis of Thromboxane B2. Tetrahedron Lett. 1976, 
17, 3279–3282. (c) Schneider, W. P.; Morge, R. A. A Synthesis of 
Crystalline Thrombxane B2 from a Derivative of Prostaglanding F2α. 
Tetrahedron Lett. 1976, 17, 3283–3286. (d) Corey, E. J.; Shibasaki, M.; 
Knolle, J.; Sugahara, T. A Direct Total Synthesis of Thromboxane B2 
(±). Tetrahedron Lett. 1977, 18, 785–788. (e) Corey, E. J.; Shibasaki, 
M.; Knolle, J. Simple, Stereocontrolled Synthesis of Thromboxane B2 
from D-Glucose. Tetrahedron Lett. 1977, 18, 1625–1626. (f) Hanes-
sian, S.; Lavallee, P. A Stereospecific, Total Synthesis of Thromboxane 
B2. Can. J. Chem. 1977, 55, 562–565. (g) Kelly, A. G.; Roberts, J. S. 
A Simple, Stereocontrolled Synthesis of a Thromboxane B2 Synthon. 
J. Chem. Soc., Chem. Commun. 1980, 228–229. (h) Hanessian, S.; La-
vallee, P. Total Synthesis of (+)-Thromboxane B2 from D-Glucose. A 
Detailed Account. Can. J. Chem. 1981, 59, 870–877. (i) Basson, M. 
M.; Holzapfel, C. W.; Verdoorn, G. H. Palladium Assisted Synthesis 
of a Thromboxane B2 Precursor. Heterocycles 1989, 29, 2261–2265. (j) 
Masaki, Y.; Yoshizawa, K.; Itoh, A. Total Synthesis of Thromboxane 
B2 Starting from (R,R)-Tartaric Acid as a Chiral Pool. Tetrahedron 
Lett. 1996, 37, 9321–9324. (k) Marvin, C. C.; Clemens, A. J. L.; Burke, 
S. D. Synthesis of Thromboxane B2 via Ketalization/Ring-Closing Me-
tathesis. Org. Lett. 2007, 9, 5353–5356.  
(9) (a) Coulthard, G.; Erb, W.; Aggarwal, V. K.  Stereocontrolled Or-
ganocatalytic Synthesis of Prostaglandin PGF2α in Seven Steps. Nature 
2012, 489, 278–281. (b) Prévost, S.; Thai, K.; Schützenmeister, N.; 
Coulthard, G.; Erb, W.; Aggarwal, V. K.  Synthesis of Prostaglandin 
Analogues, Latanoprost and Bimatoprost, Using Organocatalysis via a 
Key Bicyclic Enal Intermediate. Org. Lett. 2015, 17, 504–507. (c) 
Baars, H.; Classen, M. J.; Aggarwal, V. K.  Synthesis of Alfaprostol 
and PGF2α through 1,4-Addition of an Alkyne to an Enal Intermediate 
as the Key Step. Org. Lett. 2017, 19, 6008–6011. (d) Pelšs, A.; Gand-
hamsetty, N.; Smith, J. R.; Mailhol, D.; Silvi, M.; Watson, A. J. A.; 
Perez-Powell, I.; Prévost, S.; Schützenmeister, N.; Moore, P. R.; Ag-
garwal, V. K. Re-optimization of the Organocatalyzed Double Aldol 
Domino Process to a Key Enal Intermediate and Its Application to the 
Total Synthesis of Δ12-Prostaglandin J3. Chem. Eur. J. 2018, 24, 9542–
9545. (e) Bennett, S. H.; Coulthard,G.; Aggarwal, V. K. Prostaglandin 
Total Synthesis Enabled by the Organocatalytic Dimerization of Suc-
cinaldehyde, Chem. Rec. 2020, DOI: 10.1002/tcr.202000054 
(10) Reviews, see: (a) Das, S.; Chandrasekhar, S.; Yadav, J. S.; Grée, 
R. Recent Developments in the Synthesis of Prostaglandins and Ana-
logues. Chem. Rev. 2007, 107, 3286–3337. (b) Simeonov, S. P.; Nunes, 
J. P. M.; Guerra, K.; Kurteva, V. B.; Afonso, C. A. M. Synthesis of 
Chiral Cyclopentenones. Chem. Rev. 2016, 116, 5744–5893. (c) Peng, 
H.; Chen, F.-E. Recent Advances in Asymmetric Total Synthesis of 
Prostaglandins. Org. Biomol. Chem. 2017, 15, 6281–6301. For selected 
pioneering articles see: (d) Corey, E. J.; Weinshenker, N. M.; Schaaf, 
T. K.; Huber, W. Stereo-controlled Synthesis of Prostaglandins F2α and 
E2. J. Am. Chem. Soc. 1969, 91, 5675–5677. (e) Corey, E. J.; Schaaf, 
T. K.; Huber, W.; Koelliker, U.; Weinshenker, N. M. Total Synthesis 
of Prostaglandins F2α and E2 as the Naturally Occuring Forms. J. Am. 
Chem. Soc. 1970, 92, 397–398. (f) Corey, E. J.; Noyori, R.; Schaaf, T. 
K. Total Synthesis of Prostaglandins F1α, E1, F2α, and E2 (Natural 
Forms) from a Common Synthetic Intermediate. J. Am. Chem. Soc. 
1970, 92, 2586–2587. (g) Corey, E. J. Studies on the Total Synthesis of 
Prostaglandins. Ann. N. Y. Acad. Sci. 1971, 180, 24–37. 
(11) We have recently completed the synthesis of the non-natural fluor-
inated analogues of Thromboxane A2; see: Jing, C.; Mallah, S.; 
 
 
Kriemen, E.; Bennett, S. H.; Fasano, V.; Lennox, A. J. J.; Hers, I.; Ag-
garwal, V. K. Synthesis, Stability, and Biological Studies of Fluori-
nated Analogues of Thromboxane A2. ACS Cent. Sci. 2020, 6, 995–
1000. 
(12) (a) Forster, A.; Fitremann, J.; Renaud, P. Preparation of An Ad-
vanced Intermediate for the Synthesis of epi-Thromboxanes. Tetrahe-
dron Lett. 1998, 39, 3485–3488. (b) Leonard, J.; Ouali, D.; Rahman, S. 
K. A Short Enantioselective Route to Corynanthe Alkaloid Precursors. 
Tetrahedron Lett. 1990, 31, 739–742. 
(13) Duffy, L. A.; Matsubara, H.; Procter, D. J. A Ring Size-Selective 
Reduction of Lactones Using SmI2 and H2O. J. Am. Chem. Soc. 2008, 
130, 1136–1137. 
(14) Martynow, J. G.; Jóźwik, J.; Szelejewski, W.; Achmatowicz, O.; 
Kutner, A.; Wiśniewski, K.; Winiarski, J.; Zegrocka-Stendel, O.; 
Gołębiewski, P. A New Synthetic Approach to High‐Purity (15R)‐Lat-
anoprost. Eur. J. Org. Chem. 2007, 689–703. 
(15) Although the diastereoselectivity of the alkylation is inconsequen-
tial, it is noteworthy nonetheless and can be accounted for as follows. 
The repulsion between the oxygen lone pairs as well as overlapping of 
a p-type orbital of the ring oxygen and sp-type orbital of the exocyclic 
oxygen, increases the nucleophilicity of the cis-O-“naked” anion gen-
erated from alkoxide -21 upon deprotonation.  However, a similar en-
hancement in reactivity is not expected for trans-O-“naked” anion (See 
Figure below).  
 
For selected articles, see (a) Adderley, N. J.; Buchanan, D. J.; Dixon, 
D. J.; Lainé, D. I. Highly Diastereoselective Oxy‐Michael Additions of 
Enantiopure δ‐Lactol Anions to Nitroalkenes: Asymmetric Synthesis 
of 1,2‐Amino Alcohols. Angew. Chem. Int. Ed. 2003, 42, 4241–4244. 
(b) Buchanan, D. J.; Dixon, D. J.; Hernandez-Juan, F. A. Highly Stere-
oselective Intermolecular Oxy-Michael Addition Reaction to α,β-Un-
saturated Malonate Esters. Org. Lett. 2004, 6, 1357–1360. (c) Webb, 
D.; van den Heuvel, A.; Kögl, M.; Ley, S. V.  Enantioselective Synthe-
sis of the Lyngbouilloside Macrolactone Core. Synlett 2009, 2320–
2324. For further evidence of the mechanism, see (d) Schmidt, R. R.; 
Michel, J. Direct O-Glycosyl Trichloroacetimidate Formation, Nucle-
ophilicity of the Anomeric Oxygen Atom. Tetrahedron Lett. 1984, 25, 
821–824. (e) Fraser-Reid, B.; Mootoo, D. R.; Konradsson, P.; Udo-
dong, U. E.; Andrews, C. W.; Ratcliffe, A. J.; Wu, Z.; Yu, K. L. Novel 
Carbohydrate Transformations Discovered En Route to Natural Prod-
ucts. Pure Appl. Chem. 1989, 61, 1243–1256. (f) Dixon, D. J.; Ley, S. 
V.; Tate, E. W.  Diastereoselective Oxygen to Carbon Rearrangements 
of Anomerically Linked Enol Ethers and the Total Synthesis of (+)-
(S,S)-(cis-6-Methyltetrahydropyran-2-yl)acetic Acid, A Component of 
Civet. J. Chem. Soc. Perkin Trans. 1, 2000, 2385–2394. 
(16) We obtained full spectroscopic data (1H NMR, 13C NMR, HRMS, 
and [α]D24) of the methyl glycoside, but obtaining high quality data for 
TxB2 itself was more challenging. We were able to obtain HRMS (see 
SI), mp. 91-94 °C, and [α]D24 = +57.10 (c 1.0, EtOH) which matched 
the literature [lit.8b mp. 92.0-92.5 °C, [α]D = +56.50 (c 1.0, EtOH)]. 
However, 1H NMR spectrum of our sample was somewhat broad with 
multiple peaks, reflecting perhaps different aggregation states of the 
molecule in CDCl3. This has been documented in previous syntheses 
of TxB2.8k For comparison, we have included the 1H NMR of our sam-
ple with that of a commercial sample from Cayman in the SI.
 
